United States Next Generation Sequencing Market Size and Share Analysis - Growth Trends and Forecast Report 2024-2032

United States Next Generation Sequencing Market Trends & Summary

United States next-generation sequencing (NGS) market is set to expand from US$ 3.16 billion in 2023 up from US$ 13.75 billion by 2032, with the compound annual growth rate of 17.75 percent from 2024 to 2032. This market growth is driven by improvements in genomics technology; the trend towards the increased adoption of biotechnology and pharmacogenomics; augmented research and development expenditure in biotechnology and healthcare industries.

The report United States Next Generation Sequencing Market & Forecast covers by Products (Instruments, Reagents & Consumables, and Services), Application (Diagnostics, Agriculture and Animal Research, Drug Discovery, Personalized Medicine and Genetic Screening), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Read Time Sequencing, Nanopore Sequencing), End-Users(Academic and Clinical Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Others), and Company Analysis 2024-2032.

United States Next Generation Sequencing Market Outlooks

Next generation sequencing (NGS) is a breakthrough genome sequencing platform that can sequence huge amounts of DNA in a short period of time. Compared with conventional methods, NGS can process millions of fragments in a single run and thus more efficient and economical. This technology has revolutionized genomics since it makes it possible to accomplish mapping of the whole genome, thus making it easier for scientist to discover genetic factors that are accountable for causing diseases, study complexity heritability’s as well as dissect diverse mechanisms of biological procedures.

In the United States, New Generation Sequencing, or NGS has a wide range of uses within different sectors that comprises medicine, agriculture, and environment. In healthcare, it is used to address the challenges that are associated with phenotypic individuality; it identifies specific mutation that determines the best treatment plan for cancer patients. Furthermore, they use NGS for prenatal diagnostics to identify inherited disorders, and for studying evolution of pathogens in the context of epidemiological investigations. In agriculture the use of NGS has been used in crop breeding where genetic data is used to enhance the resilience and productivity, in environment science, NGS is used in bio dispersion and ecosystem surveys.

Moreover, increase in the occurrence of cancer in U.S. is projected to drive the NGS market. According to American Cancer Society, there will be about 2,001,140 new cases of cancer and 611,720 cancer deaths in the United States of America in 2024. Oncology is one of the major areas of application of NGS besides tumor profiling and identification of genetic mutations that can help in predicting treatment outcomes. Cancer genomics, understanding of tumors molecular characteristics as well as the progress in the field of targeted treatments are one of the leading NGS market drivers.

Growth Driver of the USA Next Generation Sequencing Market

Increasing Demand for Personalized Medicine

Increase in the prevalence of targeted therapy is an underlying growth factor for the Next Generation Sequencing (NGS) market in the United States. In the current healthcare, patients are now being treated basing on their genotyping or phenotyping, therefore NGS is important in analyzing several mutations or variations. It also allows the health care personnel to choose a specific treatment, which in turn leads to better success rates and fewer side effects. Due to more and more patients’ and doctors’ recognition of genetic testing, there are greater numbers of investments in NGS, technology, and services.

Advancements in NGS Technology

The multitudinous evolution of NGS equipment and its constant improvement are contributing to the exponential growth of the market. Advancements like higher accuracy of the sequence, faster NGS, and decrease cost makes it highly relevant for the applications in research as well as diagnostic areas. Modern bioinformatics tools and software have also developed more advanced, which help in deciphering the complicated genomic data. Technological advancements of these technologies get more users and increase the areas of application of NGS, hence more adoption in diverse fields. The acquisition of Verogen, a company which applies NGS technologies for human identification and forensic investigation was confirmed in January 2023 by QIAGEN. The acquisition of Verogen’s NGS tools, and professional services helps the company diversify its product offering.

Growing Applications in Research and Clinical Diagnostics

The dynamics of technology advancement in the field of NGS in research, diagnostics, and therapeutics are essential for growth in the market. For instance, it is widely used in genomics, transcriptomics, and epigenomics in academic and pharmaceutical research to facilitate discoveries of the diseases. In clinical context NGS improves the diagnostic yield especially in oncology and genetic disorders. Because of the NGS-based tests gaining regulatory approval, facility use of these technologies is more likely to integrate into daily practice, thus advancing the market and the care of patients. Another interesting fact about the NGS market is that various government programmes in the United States have sponsored its funding immensely. The CDC provides financing for a large number of public health-related projects, including those aimed at programs on genomic surveillance. In September 2022, The American Rescue Plan funded USD 1.7 billion to support the genomic surveillance strategies that shall be implemented across the country. From this funding, there will be a part dedicated to innovation while USD 90 million will be set to support the sustenance of Pathogen Genomics Centers of Excellence network for the coming five years. A CDC funding is used in order to promote NGS implementation in public health laboratories in order to increase their ability for the identification, characterization, and response to pathogens.

Challenges in the USA Next Generation Sequencing (NGS) Market

High Cost of Next-Generation Sequencing Implementation

Although sequencing technology has advanced significantly, the cost of NGS is still a major hurdle to its adoption across the U.S. Healthcare providers, research institutions, and pharmaceutical companies need to invest in expensive sequencing equipment, bioinformatics tools, and skilled personnel to interpret the large amounts of genetic data. Although costs decline with time, they are still a barrier to smaller labs and hospitals. Reimbursement policies for NGS-based diagnostics are also inconsistent, making it difficult for healthcare providers to make the financial case for adopting these technologies.

Data Storage, Interpretation, and Privacy Concerns

NGS produces enormous amounts of genomic data, which necessitates sophisticated storage solutions and high-performance computing to analyze and interpret results effectively. Many healthcare institutions lack the infrastructure and expertise to manage such data efficiently. Since genetic data is sensitive in nature, issues related to privacy and security come into play. Regulations such as HIPAA must be adhered to, but the data has to be secure and shared without hitches in both clinical and research applications in the U.S. market in NGS.

USA Reagents & Consumables Next Generation Sequencing Market

Reagents and consumables will be one of the significant segments in the U.S. NGS market, as continuous sequencing workflows require a steady supply of high-quality kits, chemicals, and enzymes. The increasing adoption of NGS in clinical diagnostics and research has boosted the demand for specialized reagents used in sample preparation, library construction, and sequencing reactions. Companies focus on developing more cost-effective and efficient reagents to enhance sequencing accuracy and speed. However, supply chain disruptions and stringent regulatory approvals for new reagents can impact the growth of the market and product availability.

USA Next Generation Sequencing Diagnostics Market

NGS has revolutionized diagnostics in the U.S. by allowing early detection of genetic disorders, infectious diseases, and cancer through precise genomic analysis. Advancements in personalized medicine and targeted therapies are fueling the demand for NGS-based diagnostic tests. The application of NGS in NIPT, liquid biopsies, and rare disease diagnostics by clinical laboratories and hospitals is also increasing. Such high costs, restrictions on reimbursement, and complex regulatory pathways limit the pervasive use of NGS diagnostics. Improvement in standardization and expansion of insurance are seen in efforts towards better accessibility of NGS diagnostics to the patients. Illumina Inc. launched its MiSeq™ i100 Series sequencing systems in October 2024, which brings exceptional benchtop speed and simplicity to next-generation sequencing for labs.

USA Next Generation Sequencing Drug Discovery Market

The US pharmaceutical industry uses NGS for accelerating drug discovery and development. It identifies genetic markers, explains disease mechanisms, and screens possible drug candidates. NGS facilitates precision medicine approaches by providing a treatment that matches the genetic makeup of an individual, ultimately enhancing treatment response. Rising investment by leading biotech and pharmaceutical companies in drug discovery through the lens of genomics is driving market expansion. Nevertheless, the need for strong bioinformatics capabilities to handle massive genomic data in drug development pipelines may ultimately prove to be a drag on commercialization, while regulatory challenges impede clinical trial approvals.

 USA Next Generation Sequencing by Synthesis Market

NGS-SBS is the most prevalent sequencing technology used in the United States; Illumina, a major company, uses it. NGS-SBS allows for high-throughput sequencing with a high degree of accuracy, and it is especially useful for research applications in genomics, transcriptomics, and epigenetics. The market is growing due to improvements in SBS technology that increase read lengths and reduce the cost of sequencing. Despite challenges, such as expensive equipment and proprietary chemistries, together with extensive sample preparation, this field has significant barriers to entry and accessibility. Firms continue to improve the speed and economics to make SBS more broadly useful for applications in clinical research.

USA hospitals and clinics market

The adoption of NGS in U.S. hospitals and clinics is on the rise due to its role in personalized medicine, oncology diagnostics, and infectious disease surveillance. Most leading medical institutions are adopting NGS into routine clinical workflows to enhance patient care through precision diagnostics and targeted therapies. However, smaller hospitals and community clinics face barriers such as high costs, lack of trained personnel, and reimbursement challenges. Some crucial efforts to ensure increasing adoption across the broader healthcare system include making NGS testing more accessible and simpler, costs lowered, and coverage by insurers. Further, growth in decentralized sequencing capabilities would also drive this market. Jan. 2025, Complete Genomics, a pioneering genomic sequencing company, expanded its U.S. manufacturing footprint with augmented technology capabilities to diversify its supply chain, helping it to continue reliably serving customers with flexible, cost-effective next-generation sequencing (NGS) solutions.

United States Next Generation Sequencing Company News

In January 2024, Illumina and Janssen Research & Development are collaborating to create a molecular residual disease assay to detect circulating tumor DNA and improve our understanding of disease persistence or recurrence after clinical intervention.

In May 2023, Thermo Fisher Scientific Inc. and Pfizer are partnering to expand access to next-generation sequencing testing for lung and breast cancer patients in over 30 countries across Africa, Latin America, Asia, and the Middle East. This collaboration aims to expedite the analysis of relevant genes for more informed patient therapy decisions.

In April 2023, Agilent Technologies Inc. unveiled a new NGS assay designed to advance precision oncology through comprehensive genomic profiling.

In September 2023, Neuron23, a U.S.-based biotech company, partnered with QIAGEN to create a complementary diagnostic tool for Neuron23's LRRK2 inhibitor, which is used to treat Parkinson's disease. The assay is integrated into an NGS workflow using QIAGEN's capabilities.

In April 2022, Thermo Fisher Scientific launched the Ion Torrent Genexus Dx Integrated Sequencer. This CE-IVD mCE-IVD-marked form provides results within a day, driving growth in the platform product segment.

United States Next Generation Sequencing Market Segments

Product – Market breakup in 3 viewpoints:

1. Instruments
2. Reagents & Consumables
3. Services

Application – Market breakup in 5 viewpoints:

1. Diagnostics
2. Agriculture and Animal Research
3. Drug Discovery
4. Personalized Medicine and Genetic Screening
5. Others

Technology – Market breakup in 5 viewpoints:

1. Sequencing by Synthesis
2. Ion Semiconductor Sequencing
3. Single-Molecule Read Time Sequencing
4. Nanopore Sequencing
5. Others

End-Users – Market breakup in 4 viewpoints:

1. Academic and Clinical Research Centers
2. Pharmaceutical and Biotechnology Companies
3. Hospitals and Clinics
4. Others

All the Key players have been covered from 5 Viewpoints:

• Overviews
• Key Person
• Recent Developments & Strategies
• Product Portfolio & Product Launch in Last 1 Year
• Revenue

Company Analysis:

1. Illumina
2. Thermo Fisher Scientific
3. Pacific Biosciences of California
4. QIAGEN N.V
5. Roche
6. Bio-Rad Laboratories, Inc.
7. Takara Bio Inc.
8. Hamilton Company
9. Geneious,
10. BioMérieux SA.

Report Details:

Customization Services available

• Analysis of Market Size and Its Segments
• More Company Profiles (Upto 10 without any additional cost):
• Additional Countries (Other than mentioned Countries):
• Region/Country Specific Reports:
• Market Entry Strategy:
• Region-Specific Market Dynamics:
• Regional Market Share Analysis:
• Trade Analysis:
• Production Insights:
• Others Customized Requests:

For more information contact our analysts.

Need More Assistance?

• Talk to our analysts to get more precious information on the current market trends.
• Include more countries and segments and customize the report based on the final requirement.
• Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
• Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.